Robyn Karnauskas
Stock Analyst at Truist Securities
(2.40)
# 2,518
Out of 5,139 analysts
178
Total ratings
43.79%
Success rate
0.18%
Average return
Main Sectors:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $1,038.40 | +13.83% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.12 | +142.72% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $330.41 | -9.81% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $55.26 | +17.63% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $108.83 | +1.08% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $124.91 | -33.55% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $214.35 | -2.03% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.41 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $164.42 | +106.79% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.00 | +2,511.75% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.60 | +337.50% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $733.04 | +54.83% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.90 | +426.32% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $3.02 | +198.01% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $23.13 | -0.56% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $26.27 | +82.72% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $21.80 | +129.36% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $441.36 | +15.10% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.65 | +40.35% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $72.48 | -65.51% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.84 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $54.59 | +156.46% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $3.31 | +906,244.41% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.19 | +488.24% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $22.84 | +140.81% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $7.07 | +4,426.17% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $27.15 | -44.75% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.10 | +84,645.76% | 1 | Oct 8, 2020 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $1,038.40
Upside: +13.83%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.12
Upside: +142.72%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $330.41
Upside: -9.81%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $55.26
Upside: +17.63%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $108.83
Upside: +1.08%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $124.91
Upside: -33.55%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $214.35
Upside: -2.03%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.41
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $164.42
Upside: +106.79%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.00
Upside: +2,511.75%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.60
Upside: +337.50%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $733.04
Upside: +54.83%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.90
Upside: +426.32%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $3.02
Upside: +198.01%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $23.13
Upside: -0.56%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $26.27
Upside: +82.72%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $21.80
Upside: +129.36%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $441.36
Upside: +15.10%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.65
Upside: +40.35%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $72.48
Upside: -65.51%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.84
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $54.59
Upside: +156.46%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $3.31
Upside: +906,244.41%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.19
Upside: +488.24%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $22.84
Upside: +140.81%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $7.07
Upside: +4,426.17%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $27.15
Upside: -44.75%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.10
Upside: +84,645.76%